USA flag logo/image

An Official Website of the United States Government

Neurorestorative Strategy for Chemotherapy-induced Peripheral Neuropathy

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
93581
Program Year/Program:
2009 / SBIR
Agency Tracking Number:
CA141819
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
COGNOSCI, INC.
79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709-2076
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2009
Title: Neurorestorative Strategy for Chemotherapy-induced Peripheral Neuropathy
Agency: HHS
Contract: 1R43CA141819-01
Award Amount: $326,711.00
 

Abstract:

DESCRIPTION (provided by applicant): Chemotherapy-induced peripheral neuropathy (CIPN) is a major dose-limiting side effect of many commonly used chemotherapeutic agents, including platinum drugs and taxanes. CIPN, characterized by peripheral axonal degene ration and demyelination, can be disabling and extremely painful, causing significant loss of functional abilities and decreasing quality of life. Considering the incidence of CIPN vary from 30 to 40% of patients receiving chemotherapy, the total populatio n affected by CIPN is enormous. Although some preventive strategies have been proposed to attenuate the development of CIPN, effective treatment of established CIPN has yet to be found. Therefore, a neurorestorative strategy to repair damaged axons is stil l critically needed to alleviate the symptom of established CIPN. Cognosci has innovatively created and characterized a series of peptides derived human apolipoprotein E (apoE), which are generally designated as COG compounds. Extensive studies have demons trated that COG compounds exert potent anti-inflammatory activities, neuroprotective and neurorestorative activities both in vitro and in vivo. We have also obtained data showing that COG112, one of the most potent apolipoprotein E mimetics, can significan tly prevent axonal degeneration and promote axonal regeneration and remyelination in a sciatic nerve crush model. A similar neuroprotective effect has been validated in animal models of a variety of neurological disorders such as traumatic brain injury, sp inal cord injury, subarachnoid hemorrhage and multiple sclerosis, implicating a therapeutic efficacy for these diseases. Furthermore, Cognosci had successfully identified the binding protein of COG compounds, which is SET, an endogenous inhibitor of serine /threonine protein phosphatase 2A (PP2A). SET is well known as a nuclear oncogene and has been associated with several types of cancers, such as chronic lymphocytic leukemia (CLL), myeloid leukemia. With ongoing program to develop COG112 as anticancer drug , here we propose to examine whether COG112 can prevent the neuotoxicity of chemotherapies, repair histological damage and restore the lost functions of established CIPN in the following aspects: 1) Specific aim 1: To examine the potential neuroprotective and neuroregenerative effects of COG112 in a cisplatin and paclitaxel-induced axonal damage and neuronal cell death in primary dorsal root ganglion (DRG) cultures; 2) Specific Aim 2: To examine if COG112 exerts neuroprotective and neurorestorative effects by histological and functional examination in a cisplatin-induced CIPN animal model. PUBLIC HEALTH RELEVANCE: The overall goal of this project is to obtain proof of concept that COG112 can be a therapeutic agent for chemotherapy induced peripheral neuropat hy with dual favorable properties of neuroprotection and neurorestoration. Moreover, COG112 can either independently inhibit cancer growth or be combined with other anticancer drugs to enhance their therapeutic activity but to reduce their neurotoxic side effects. If substantiated by this study, COG112 may represent a promising therapy for both cancer and chemotherapy induced peripheral neuropathy.

Principal Investigator:

Fengqiao Li
9197650028
FLI@COGNOSCI.COM

Business Contact:

Michael P. Vitek
mikevitek@cognosci.com
Small Business Information at Submission:

COGNOSCI, INC.
COGNOSCI, INC. 79 T. W. Alexander Drive RESEARCH TRIANGLE PARK, NC 27709

EIN/Tax ID: 562208520
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No